David Rekhtman

David Rekhtman

Auto-generated profile, based on publicly available information

David Rekhtman

Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
SKSamuel T. Kim
Samuel T. Kim
AIAmit Iyengar
Amit Iyengar
MHMark R. Helmers
Mark R. Helmers
NWNoah Weingarten
Noah Weingarten
DRDavid Rekhtman
David Rekhtman
PAPavan Atluri
Pavan Atluri
Background: Little is known regarding the impact of donor COVID‐19 status on recipient outcomes after heart transplantation. In this study, we characterize outcomes of the first 110 heart transplants from organ donors positive for COVID‐19 (COVID‐19+) in the United States. Methods and Results: Retrospective analysis of the United Network for Organ Sharing database was performed for single‐organ adult heart transplants from January 2020 to March 2022. Donor COVID‐19+ status was defined as a positive nucleic acid amplification, antigen, or other COVID‐19 test within 7 days of transplant. Nearest‐neighbor propensity score matching used to adjust for differences between recipients of COVID‐19+ and nonpositive donor hearts. Overall, 7251 heart transplants were included in analysis, with 110 using COVID‐19+ donor hearts. Recipients of COVID‐19+ allografts were younger (54 [interquartile range, 41–61]) versus 57 [46–64] years; P =0.02) but had similar rates of female sex and non‐White race compared with those receiving allografts from negative donors. Nearest‐neighbor propensity score matching resulted in 100 well‐matched pairs of recipients of COVID‐19+ versus nonpositive donor organs. The 2 matched groups had similar median lengths of stay (15 [11–23] days versus 15 [13–23] days; P =0.40), rates of graft failure (1% versus 0%; P =0.99), 30‐day death (3% versus 3%; P =0.99), and 3‐month survival (88% versus 94%; P =0.23) compared with recipients of nonpositive donors. No deaths occurred due to COVID‐19 infection among the 8 (7%) total deceased recipients of COVID‐19+ allografts to date. Conclusions: Short‐term outcomes of heart transplant recipients receiving COVID‐19+ donor organs are reassuring. However, continued monitoring for long‐term survival and potential complications are warranted.

17 April 2025 in ASAIO Journal
Verified
Journal Article
Closed access
MAMichaela Asher
Michaela Asher
AIAmit Iyengar
Amit Iyengar
DRDavid Rekhtman
David Rekhtman
MHMark Helmers
Mark Helmers
NWNoah Weingarten
Noah Weingarten
MCMarisa Cevasco
Marisa Cevasco
We sought to investigate the hemodynamic and echocardiographic consequences of the Impella 5.5 during the acute perioperative period. A retrospective analysis of patients who underwent device implantation at our institution between January 2021 and June 2023 was performed. Hemodynamic and echocardiographic changes were modeled as linear mixed models with random intercepts for patient and fixed as well as random effects of time. Of 87 patients identified, most were male (72, 83%) with nonischemic cardiomyopathy (44, 51%). In the first two postoperative days, the median cardiac output increased by 1.2 L/min (p < 0.05), although the median Impella flow remained at 4.1 L/min. Mean pulmonary artery pressures (32 vs. 27 mm Hg, p < 0.05) and vasoactive inotrope scores (5.6 vs. 3.7, p < 0.01) were modestly reduced. Significant echocardiographic improvement was noted in 61% and 71% of patients with significant preoperative mitral or tricuspid regurgitation, respectively. However, no changes in ejection fraction, left ventricle (LV) diameter, or right ventricular function were noted (all p > 0.05). At 30 days, 27 (31%) patients were transplanted and 13 (15%) were bridged to a durable left ventricular assist device (LVAD). We conclude that in the acute phase following Impella implantation, LV offloading, reductions in pulmonary artery pressures, and improvement in valvular regurgitation are seen without changes to ventricular geometry.

15 July 2025 in JHLT Open
Verified
Journal Article
Open access
MAMichaela Asher
Michaela Asher
DRDavid Rekhtman
David Rekhtman
AIAmit Iyengar
Amit Iyengar
JDJohn DePaolo
John DePaolo
CSCindy Song
Cindy Song
MCMarisa Cevasco
Marisa Cevasco
We sought to compare the outcomes of Impella 5.5 use between sexes. All adult patients who underwent Impella 5.5 implantation at the University of Pennsylvania and Columbia University between June 2020 and May 2024 were retrospectively reviewed. Demographics, baseline status, complications, and outcomes were compared between sexes. Laboratory values were examined with a linear mixed model, and a parsimonious multivariable logistic regression was developed to assess factors predictive of in-hospital mortality. Of 254 patients, 41 (16%) were female and 213 (84%) were male. Before implant, females had lower hemoglobin levels (9.6 vs 11.2 g/dl, p < 0.05), but similar cardiac risk factors (all p > 0.05). The smaller size of females did not preclude device implantation (height: 1.7 vs 1.8 m; weight: 74.8 vs 88.0 kg, all p < 0.05), and only 1 out of 41 (2.4%) females required direct aortic placement due to prohibitive anatomy. Preimplant mechanical circulatory support, duration of support, and postimplant rates of stroke, infection, and bleeding were similar (all p > 0.05). In addition, laboratory biocompatability markers did not differ between sexes, nor did rates of successful bridging to durable therapies (all p > 0.05). Finally, in-hospital and 1-year mortality were similar (all p > 0.05), and female sex was not identified as a risk factor for in-hospital mortality (odds ratio 0.91, p > 0.05). Females do not experience increased complications from the Impella 5.5, nor reduced device biocompatibility. Our data support greater consideration of device use in females.

18 January 2025 in JHLT Open
Verified
Journal Article
Open access
AIAmit Iyengar
Amit Iyengar
JFJason Feinman
Jason Feinman
JJJoyce Jiang
Joyce Jiang
CSCindy Song
Cindy Song
SKSpencer Kim
Spencer Kim
APAditya Parikh
Aditya Parikh
Left ventricular assist device-specific infections (LSIs) remain a persistent problem facing patients with durable left-ventricular assist devices (LVADs). However, the infectious agents and associated morbidity remained poorly defined. We sought to evaluate the incidence, epidemiology, and morbidity associated with LSIs in patients receiving modern centrifugal LVADs at 2 tertiary care centers. Retrospective analysis was performed of adult patients receiving HeartMate 3 implants at the University of Pennsylvania and Mount Sinai Health Systems from January 1, 2015 to March 31, 2021, with follow-up until March 31, 2022. Patients were grouped by history of LSI, defined as culture-positive infections and/or those requiring medical or surgical intervention. Demographic data, available culture data, medical interventions, and surgical interventions were queried. Survival analysis was censored at 4 years and landmarked according to 25th percentile time-to-infection. Among 206 LVAD recipients, 71 (34.5%) developed an LSI. Predominant organisms were Staphylococcus (47.9%), Pseudomonas (15.5%), and Serratia (8.5%). Predictors of infection included Black race (LSI vs No LSI: 46.2% vs 29.2%, p = 0.021) and body mass index (median 29.7 vs 26.2 kg/m2, p = 0.007). Median time to infection was 231 days (112−423), with 19 (26.8%) patients requiring surgical debridement. Landmarked survival did not differ (log-rank p = 0.830). LSI patients were hospitalized an extra 8 (0−28) days for infection-related reasons. LSIs remain pervasive, with most related to Staphylococcus, Pseudomonas, and Serratia, and are associated with significantly increased rehospitalization burden. Surgical interventions were utilized in 26.8% of patients. Continued efforts to understand and prevent LSIs are necessary to improve care for LVAD patients.

19 February 2023 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
MSMax Shin
Max Shin
AIAmit Iyengar
Amit Iyengar
MHMark R. Helmers
Mark R. Helmers
WPWilliam L. Patrick
William L. Patrick
WCWilliam Cohen
William Cohen
MCMarisa Cevasco
Marisa Cevasco

29 September 2023 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
MSMax Shin
Max Shin
AIAmit Iyengar
Amit Iyengar
MHMark R. Helmers
Mark R. Helmers
CSCindy Song
Cindy Song
DRDavid Rekhtman
David Rekhtman
MCMarisa Cevasco
Marisa Cevasco